DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Boehringer Ingelheim
Boehringer Ingelheim
A Forum Report on Continuous Manufacturing for Biologics
A Phase Ib/II Study of Xentuzumab, an IGF-Neutralising Antibody
Declarations of Interest Thorax: First Published As 10.1136/Thoraxjnl-2016-209333.476 on 15 November 2016
Johnson & Johnson and Pfizer Inc., Analysis of Agreement Containing
Producing Value
PRESCRIBING INFORMATION ------WARNINGS and PRECAUTIONS------These Highlights Do Not Include All the Information Needed to Use JARDIANCE Safely and Effectively
Disclosures
Kansas Medical Assistance Program
Declarations of Interest Thorax: First Published As 10.1136/Thoraxjnl-2016-209333.467 on 15 November 2016
Clinical Policy: Aspirin/Dipyridamole (Aggrenox) Reference Number: PA.CP.PMN.20 Effective Date: 01/18 Coding Implications Last Review Date: 07/18 Revision Log
Aspirin/Extended-Release Dipyridamole (Aggrenox)
Medical Affairs and Scientific Communications Fellowship About Us
Amgen Obtains Global Development and Commercial Rights from Boehringer Ingelheim for Investigational Bite® Immuno-Oncology Drug for Multiple Myeloma
Group Management Report
Template That Creates a Custom Pleading
A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced Or Metastatic Fibroblast Activation Protein-Positive Cancer1
HIGHLIGHTS of PRESCRIBING INFORMATION Thereafter Or As Clinically Indicated
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Top View
Effect of Trilaciclib, a CDK 4/6 Inhibitor, on Myelosuppression in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer
Aptivus Label
Aptivus® Prescribing Information
Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors
Our Clinical Trials
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated
The ASCO Post Editor Conflict of Interest Disclosures
(OPCG) and Boehringer Ingelheim Pharmaceuticals, Inc
Faldaprevir Boehringer Ingelheim
Value Through Innovation F I N a N C I a L H I G H L I G H T S S U M M a R Y R E P O R T
BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells S
2020 Medicines in Development ꟷ Cancer
PRESCRIBING INFORMATION • Interstitial Lung Disease (ILD): Occurs in 1.6% of Patients
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Press Release for Immediate Distribution CQDM Welcomes Two
1 Annual Declaration of Interests Global Initiative
Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP- Competitive Inhibitor of MEK and Aurora Kinases
G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update
PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use ------CONTRAINDICATIONS------TWYNSTA Safely and Effectively
G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico
Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia
The Largest Pharmaceutical Companies Worldwide Analysis of Key Financial Indicators for Fiscal Years 2017, 2018 and 2019 About the Study
BI-3406, a Potent and Selective SOS1::KRAS Interaction
Breast Cancer
AGGRENOX Safely and Effectively
Use of Metformin and Cardiovascular Effects of New
Risk Stratification and Medical Therapy of Pulmonary Arterial Hypertension
G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
Boehringer Ingelheim and OSE Immunotherapeutics Announce
Global Initiative for Chronic Obstructive Lung Disease (Gold) Disclosure of Financial Interest
An Overview of the 6Th World Symposium on Pulmonary Hypertension
United States District Court District of Connecticut In
(19) United States (12) Patent Application Publication (10) Pub
Quantifying CDK Inhibitor Selectivity in Live Cells
APTIVUS (Tipranavir) Label
Complaint (PDF)
The Kinase Chemogenomic Set (KCGS): an Open Science Resource for Kinase Vulnerability Identification
Tipranavir (Aptivus) FACT SHEET Summary Published Tipranavir Is a Type of Anti-HIV Drug Called a Protease Inhibitor
Acknowledgements
R IMMEDI QDM Welc Gelheim A
FDA Approves G1 Therapeutics' COSELA™ (Trilaciclib)
David Price – Conflict of Interest Statement